Aastrom Moves Cell Therapy To The Verge Of Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aastrom Biosciences Inc. is on the verge of entering Phase III with its first biologic, the cell therapy ixmyelocel-T, now that the Michigan biotech has finally nailed down the specifics of a Special Protocol Assessment with FDA.